The Treatment of Lichen Sclerosus with Topical Roflumilast 0.3% Case Study
Main Article Content
Keywords
Lichen Sclerosus, Topical Roflumilast 0.3%, Lichen Sclerosus treated with topical roflumilast 0.3% once daily
Abstract
Lichen Sclerosus is a chronic inflammatory skin disease predominantly affecting post-menopausal women. Currently, the first line treatment approach for lichen sclerosus is ultra potent topical corticosteroids for 12 weeks. A treatment challenge to this approach is the risk of steroid atrophy due to the use of potent topical steroids on the genital skin. We describe reduction of erythema and symptomatic improvement following treatment with topical roflumilast 0.3% once daily in a patient with lichen sclerosus who refused topical corticosteroids.
References
2. Altman, DA. Palmoplantar pustulosis successfully treated with topical roflumilast 0.3%. Journal of Dermatology for Physician Assistants 2024.18(3):p 34-35. DOI: 10.1097/jdpa.0000000000000027
3. ZORYVE (roflumilast) topical cream [prescribing information online]. Westlake Village, CA: Arcutis Biotherapeutics. July 2022. Available at: USPI-roflumilast-cream-FDAapproved-V1-29Jul2022.pdf (arcutis.com). Accessed
4. Stacey SK and Mceleney M. Topical Corticosteroids: Choice and Application; American Family Physician. 2021;103(6):337-343.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.